|
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma.
|
30872780 |
2019 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
|
31801186 |
2019 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Characteristics of CD5-positive diffuse large B-cell lymphoma among Koreans: High incidence of BCL2 and MYC double-expressors.
|
31644584 |
2019 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemically detectable co-expression of MYC and BCL2 in the absence of translocations also portends an increased risk of relapse within the central nervous system, particularly in the setting of the activated B-cell-like subtype of diffuse large B-cell lymphoma.
|
30573511 |
2019 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Specific interactions of BCL-2 family proteins mediate sensitivity to BH3-mimetics in diffuse large B-cell lymphoma.
|
31601689 |
2019 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently, high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements have been categorized separately from diffuse large B-cell lymphoma or BL.
|
31229156 |
2019 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Clinical Significance of <i>BCL2</i>, C-<i>MYC</i>, and <i>BCL6</i> Genetic Abnormalities, Epstein-Barr Virus Infection, CD5 Protein Expression, Germinal Center B Cell/Non-Germinal Center B-Cell Subtypes, Co-expression of MYC/BCL2 Proteins and Co-expression of MYC/BCL2/BCL6 Proteins in Diffuse Large B-Cell Lymphoma: A Clinical and Pathological Correlation Study of 120 Patients.
|
31171907 |
2019 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Primary cardiac diffuse large B-cell lymphoma with concurrent high MYC and BCL2 expression in an immunocompetent Chinese elderly woman.
|
28985492 |
2018 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Drug-induced aneuploidy and polyploidy is a mechanism of disease relapse in MYC/BCL2-addicted diffuse large B-cell lymphoma.
|
30542505 |
2018 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interim 18F-FDG PET/CT and BCL2 for predicting the prognosis of patients with diffuse large B-cell lymphoma in the rituximab era.
|
29189488 |
2018 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-cell lymphoma.
|
29666157 |
2018 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Double-expressor lymphoma (DEL) is a diffuse large B cell lymphoma that exhibits co-expression of MYC and BCL2 proteins by immunohistochemistry.
|
29037890 |
2018 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Prognostic significances of overexpression MYC and/or BCL2 in R-CHOP-treated diffuse large B-cell lymphoma: A Systematic review and meta-analysis.
|
29674626 |
2018 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our results suggest that immunohistochemically defined COO remains a useful tool for predicting prognosis in diffuse large B-cell lymphoma when performed under optimized standardized conditions and that BCL2 expression may help to identify elderly patients at risk for relapse and who could potentially respond to anti-BCL2 targeted agents.
|
28327893 |
2017 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The prognostic role of Bcl-2, Ki67, c-MYC and p53 in diffuse large B-cell lymphoma.
|
29250662 |
2017 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Simultaneous Drug Targeting of the Promoter MYC G-Quadruplex and BCL2 i-Motif in Diffuse Large B-Cell Lymphoma Delays Tumor Growth.
|
28605593 |
2017 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Diffuse large B-cell lymphoma with concurrent high MYC and BCL2 expression shows evidence of active B-cell receptor signaling by quantitative immunofluorescence.
|
28212447 |
2017 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition.
|
29269870 |
2017 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
BCL-2 and MYC gain/amplification is correlated with central nervous system involvement in diffuse large B cell lymphoma at leukemic phase.
|
28209136 |
2017 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma.
|
27739436 |
2017 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Negative impact of concurrent overexpression of MYC and BCL2 in patients with advanced diffuse large B-cell lymphoma treated with dose-intensified immunochemotherapy.
|
27071312 |
2016 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
High expression of Bcl-2 predicts poor outcome in diffuse large B-cell lymphoma patients with low international prognostic index receiving R-CHOP chemotherapy.
|
26586460 |
2016 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B-cell lymphoma.
|
27027803 |
2016 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma.
|
26467384 |
2016 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Sixty-nine cases of diffuse large B-cell lymphoma were evaluated for MYC and BCL2 protein expression using various cut-offs that have been recommended in prior studies.
|
26421520 |
2016 |